HZX-02-059

Overview

HZX-02-059 is an allosteric inhibitor of PIKFYVE , and a methuosis inducer. HZX-02-059 disrupts the PIKfyve / TFEB axis, suppresses tubulin polymerization, reduces phosphorylated mTOR levels, downregulates p53 , PI3K/AKT , c-Myc , and NF-κB pathways . HZX-02-059 induces G 2 /M cell cycle arrest, apoptosis , and inhibits cancer cell proliferation. HZX-02-059 can be used for the research of lymphoma, double-hit lymphoma, and B-cell acute lymphoblastic leukemia.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Microtubule/Tubulin | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-112440
• CAS No.: 2240205-30-3
• Molecular Formula: C27H20F3N5O
• Molecular Weight: 487.48
• Purity: 99.40%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (5.13 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source